OBJECTIVES: To evaluate characteristics of Streptococcus pneumoniae associated with oropharyngeal colonization in the Ugandan adult HIV population. METHODS: We conducted a cross-sectional study at the outpatient HIV clinic at the Joint Clinical Research Centre in Kampala, Uganda between July 2004 and February 2005. Six hundred HIV-infected individuals were interviewed and had oropharyngeal specimens collected. Pneumococci were isolated from these specimens and antimicrobial susceptibility patterns determined using standard microdilution methods. Serotypes of the pneumococcal isolates were evaluated by capsular swelling reaction with commercial antisera. RESULTS: The prevalence of oropharyngeal colonization with pneumococci was 18% (108/600). Thirty-two different pneumococcal serotypes were identified, and the most common were serotypes 3 (14.7%), 19F (6.4%), 23F (6.4%), and 16 (5.5%). Seventy-two percent of the isolates were penicillin (PCN) intermediate (MICs 0.12-1 microg/mL), the remainder all being PCN susceptible, and >99% were trimethoprim-sulfamethoxazole (TMP-SMX) resistant. Novel PCN intermediate serotypes included 7, 11, 16, 20, 22, 24, and 34. Only one isolate was resistant to macrolides, and resistance to other antibiotics was rare. CONCLUSIONS: HIV-infected adults in Uganda are colonized with pneumococci that exhibit a high degree of TMP-SMX and PCN non-susceptibility, with several unique PCN non-susceptible serotypes that are not included in current vaccine preparations.
OBJECTIVES: To evaluate characteristics of Streptococcus pneumoniae associated with oropharyngeal colonization in the Ugandan adult HIV population. METHODS: We conducted a cross-sectional study at the outpatient HIV clinic at the Joint Clinical Research Centre in Kampala, Uganda between July 2004 and February 2005. Six hundred HIV-infected individuals were interviewed and had oropharyngeal specimens collected. Pneumococci were isolated from these specimens and antimicrobial susceptibility patterns determined using standard microdilution methods. Serotypes of the pneumococcal isolates were evaluated by capsular swelling reaction with commercial antisera. RESULTS: The prevalence of oropharyngeal colonization with pneumococci was 18% (108/600). Thirty-two different pneumococcal serotypes were identified, and the most common were serotypes 3 (14.7%), 19F (6.4%), 23F (6.4%), and 16 (5.5%). Seventy-two percent of the isolates were penicillin (PCN) intermediate (MICs 0.12-1 microg/mL), the remainder all being PCN susceptible, and >99% were trimethoprim-sulfamethoxazole (TMP-SMX) resistant. Novel PCN intermediate serotypes included 7, 11, 16, 20, 22, 24, and 34. Only one isolate was resistant to macrolides, and resistance to other antibiotics was rare. CONCLUSIONS:HIV-infected adults in Uganda are colonized with pneumococci that exhibit a high degree of TMP-SMX and PCN non-susceptibility, with several unique PCN non-susceptible serotypes that are not included in current vaccine preparations.
Authors: D R Park; V L Sherbin; M S Goodman; A D Pacifico; G D Rubenfeld; N L Polissar; R K Root Journal: J Infect Dis Date: 2001-06-26 Impact factor: 5.226
Authors: David Felmingham; Anthony R White; Michael R Jacobs; Peter C Appelbaum; James Poupard; Linda A Miller; Reuben N Grüneberg Journal: J Antimicrob Chemother Date: 2005-10 Impact factor: 5.790
Authors: Robertino M Mera; Linda A Miller; Justin J D Daniels; John G Weil; Anthony R White Journal: Diagn Microbiol Infect Dis Date: 2005-03 Impact factor: 2.803
Authors: Manuel L Fernández Guerrero; Jose M Ramos; Jorge Marrero; Manuel Cuenca; Ricardo Fernández Roblas; Miguel de Górgolas Journal: Int J Infect Dis Date: 2003-03 Impact factor: 3.623
Authors: Mark E Jones; Renée S Blosser-Middleton; Clyde Thornsberry; James A Karlowsky; Daniel F Sahm Journal: Diagn Microbiol Infect Dis Date: 2003-12 Impact factor: 2.803
Authors: Moses L Joloba; Benson R Kidenya; David P Kateete; Fred A Katabazi; Julian K Muwanguzi; Benon B Asiimwe; Simon P Alarakol; Jessica L Nakavuma; Saralee Bajaksouzian; Anne Windau; Michael R Jacobs Journal: Int J Antimicrob Agents Date: 2010-05-15 Impact factor: 5.283
Authors: C J Gill; V Mwanakasale; M P Fox; R Chilengi; M Tembo; M Nsofwa; V Chalwe; L Mwananyanda; D Mukwamataba; B Malilwe; D Champo; W B Macleod; D M Thea; D H Hamer Journal: J Infect Dis Date: 2008-04-01 Impact factor: 5.226
Authors: Richard Kityamuwesi; Louis Muwaz; Arabat Kasangaki; Henry Kajumbula; Charles Mugisha Rwenyonyi Journal: BMC Microbiol Date: 2015-02-25 Impact factor: 3.605
Authors: Ann Lindstrand; Joan Kalyango; Tobias Alfvén; Jessica Darenberg; Daniel Kadobera; Freddie Bwanga; Stefan Peterson; Birgitta Henriques-Normark; Karin Källander Journal: PLoS One Date: 2016-11-09 Impact factor: 3.240
Authors: D M Ssebuliba; R Ouifki; C Pretorius; S M Burnett; M K Mbonye; S Naikoba; K Willis; M R Weaver Journal: Epidemiol Infect Date: 2016-09-27 Impact factor: 4.434
Authors: Richard A Adegbola; Rodrigo DeAntonio; Philip C Hill; Anna Roca; Effua Usuf; Bernard Hoet; Brian M Greenwood Journal: PLoS One Date: 2014-08-01 Impact factor: 3.240
Authors: Laura M Conklin; Godfrey Bigogo; Geofrey Jagero; Lee Hampton; Muthoni Junghae; Maria da Gloria Carvalho; Fabiana Pimenta; Bernard Beall; Thomas Taylor; Brian Plikaytis; Kayla F Laserson; John Vulule; Chris Van Beneden; Cynthia G Whitney; Robert F Breiman; Daniel R Feikin Journal: BMC Infect Dis Date: 2016-01-16 Impact factor: 3.090